Stockholm-based Neko Health, the body-scanning preventative healthcare tech firm co-founded by CEO Hjalmar Nilsonne and Spotify founder Daniel Ek, announced the completion of a $260 million Series B funding.
The round was led by Lightspeed Venture Partners, with participation from General Catalyst, O.G. Venture Partners, Rosello, Lakestar and Atomico. As part of this funding round, BejulSomaia, Partner at Lightspeed Venture Partners, will join the board at Neko Health.
“Nearly two years post launch (February 2023), Neko Health has completed 10,000 scans across Stockholm and London,” said Neko Health.
“On average, 80% of members book and prepay a scan for the following year at the end of their appointment.
“Demand remains high, with the global waiting list totalling more than 100,000. In response, the company is building out capacity with further locations and new regions.”
BejulSomaia, Global Partner, Lightspeed Venture Partners, said: “After meeting Hjalmar, Daniel and their team, it was clear Neko Health wasn’t just building another healthcare company – they were fundamentally rethinking how we approach prevention.
“Neko combines breakthrough technology with meticulous attention to detail in everything from their scanning technology to the patient experience.
“With a long waitlist and a clear path to international expansion, we believe comprehensive preventive care can be both accessible and scalable. Lightspeed is incredibly excited to support Neko Health’s mission of keeping people healthier for longer.”
The announcement follows Neko Health’s Series A funding of $65m in July 2023, which saw Lakestar, Atomico and General Catalyst join original investors Prima Materia.
“The company’s vision is to create a healthcare system that can help people stay healthy, through preventative measures and early detection,” said Neko Health.
“The unique, non-invasive Neko Health Scan costs £299 and maps millions of health data points on the body — both inside and out — in just a few minutes.
“It checks moles and marks across the body, symptoms of metabolic syndrome and risk factors for stroke and heart attack, along with blood sugar levels to assess pre-diabetes risk.
“Additionally, it checks for skin cancer and blood abnormalities. Immediately following the scan, members receive full results as part of a doctor-led consultation. The whole experience is complete in just under an hour.
CEO Nilsonne said “We’re at the beginning of a big shift of the healthcare market, from reactive to proactive, driven both by technological advancements and growing consumer demand.
“This round of financing accelerates Neko’s global expansion of locations to include the US, as well as investments in breakthrough R&D.
“In the coming years Neko will continue to bring incredible innovations to the market to find and prevent disease before it has a chance to develop.”